The 36-month beta value for KALA is also noteworthy at -1.97. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for KALA is 5.32M, and at present, short sellers hold a 5.53% of that float. The average trading volume of KALA on June 26, 2025 was 60.90K shares.
KALA) stock’s latest price update
Kala Bio Inc (NASDAQ: KALA) has seen a rise in its stock price by 17.50 in relation to its previous close of 4.0. However, the company has experienced a 12.44% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-29 that ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 5, 2025 at 1:25 p.m. ET. Management will also be available for one-on-one meetings on Thursday, June 5, 2025.
KALA’s Market Performance
Kala Bio Inc (KALA) has seen a 12.44% rise in stock performance for the week, with a 16.34% gain in the past month and a -29.85% plunge in the past quarter. The volatility ratio for the week is 9.26%, and the volatility levels for the past 30 days are at 6.84% for KALA. The simple moving average for the past 20 days is 13.40% for KALA’s stock, with a -20.51% simple moving average for the past 200 days.
Analysts’ Opinion of KALA
Jefferies gave a rating of “Hold” to KALA, setting the target price at $10 in the report published on September 14th of the previous year.
KALA Trading at 23.68% from the 50-Day Moving Average
After a stumble in the market that brought KALA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.04% of loss for the given period.
Stock Fundamentals for KALA
The total capital return value is set at -1.57. Equity return is now at value -576.46, with -70.40 for asset returns.
Based on Kala Bio Inc (KALA), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at -1.59. The debt to equity ratio resting at 3.02. The interest coverage ratio of the stock is -12.27.
Currently, EBITDA for the company is -40.98 million with net debt to EBITDA at 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.99.
Conclusion
In summary, Kala Bio Inc (KALA) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
